Stage III endometrial cancer: preoperative predictability, prognostic factors, and treatment outcome.

[1]  A. Berchuck,et al.  Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Ramirez,et al.  Surgical Staging for Patients Presenting With Grade 1 Endometrial Carcinoma , 2005, Obstetrics and gynecology.

[3]  D. Bodurka,et al.  Predictors of final histology in patients with endometrial cancer. , 2004, Gynecologic oncology.

[4]  D. Bodurka,et al.  Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. , 2004, Journal of the American College of Surgeons.

[5]  P. Roland,et al.  The benefits of a gynecologic oncologist: a pattern of care study for endometrial cancer treatment. , 2004, Gynecologic oncology.

[6]  P. Maisonneuve,et al.  Carcinoma of the corpus uteri , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[7]  J. Stromberg,et al.  Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation. , 2003, Gynecologic oncology.

[8]  Chao-Cheng Huang,et al.  Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? , 2002, Gynecologic oncology.

[9]  Kenichi Tanaka,et al.  Stage III endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy. , 2001, Gynecologic oncology.

[10]  J. Fanning,et al.  Survival after multimodality treatment for stage IIIC endometrial cancer. , 2001, American journal of obstetrics and gynecology.

[11]  R. Bentley,et al.  The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. , 2000, Gynecologic oncology.

[12]  K. Gerszten,et al.  Pathologic stage III endometrial cancer treated with adjuvant radiation therapy. , 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[13]  R. Burger,et al.  Value of Preoperative CA 125 Level in the Management of Uterine Cancer and Prediction of Clinical Outcome , 1997, Obstetrics and gynecology.

[14]  J. Schorge,et al.  The effect of postsurgical therapy on stage III endometrial carcinoma. , 1996, Gynecologic oncology.

[15]  M. R. Smith,et al.  Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. , 1994, American journal of obstetrics and gynecology.

[16]  B. Corn,et al.  Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence , 1993, Cancer.

[17]  V. Abeler,et al.  Endometrial adenocarcinoma in Norway. A study of a total population , 1991, Cancer.

[18]  W. Mann,et al.  Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma , 1988, American journal of obstetrics and gynecology.

[19]  B. Bundy,et al.  Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study , 1987, Cancer.

[20]  H. D. de Bruijn,et al.  CA 125: A useful marker in endometrial carcinoma , 1987, American journal of obstetrics and gynecology.

[21]  J. Thigpen,et al.  Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[23]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[24]  A. Ayhan,et al.  Surgical stage III endometrial cancer: analysis of treatment outcomes, prognostic factors and failure patterns. , 2002, European journal of gynaecological oncology.

[25]  Y. Taketani,et al.  Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. , 1997, British Journal of Cancer.

[26]  E. Partridge,et al.  Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. , 1995, Gynecologic oncology.

[27]  W. Creasman,et al.  Recent advances in endometrial cancer. , 1990, Seminars in surgical oncology.

[28]  T. Ulbright,et al.  Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. , 1985, Human pathology.